Skip to main content

Editas Medicine, Inc.

EDIT
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001650664

In the last 90 days, Editas Medicine, Inc. insiders filed 0 open-market purchases and 5 sales; 215 institutions reported holding it in 13F filings for Q2 2026, worth $389.6M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Editas Medicine, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
5 filings
3 insiders, $34.0K in total
Insiders trading
3
Net value
−$34.0K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Editas Medicine, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Editas Medicine, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Ory Daniel ScottEVP, Chief Medical Officer–Sep 9, 20261
Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER61,660Sep 4, 20266
Parison AmySVP, Chief Financial Officer13,839Sep 4, 20266
O'Neill Gilmore NeilCEO243,189Sep 4, 20265
Ellinor Patrick Thomas IIDirector–Aug 7, 20261
Hirsch AndrewDirector–Jun 22, 20261
Hopfield JessicaDirector67,700Jun 22, 20261
Connaughton BernadetteDirector–Jun 22, 20261
Scadden DavidDirector–Jun 22, 20261
Levy Elliott M.Director–Jun 22, 20261
Lucera ErickEVP, CHIEF FINANCIAL OFFICER112,720Mar 27, 20250
Mei BaisongEVP, CHIEF MEDICAL OFFICER133,354Dec 5, 20240
Vaishnaw AkshayDirector–Jun 3, 20240
Reeve EmmaDirector–Jun 3, 20240
Chatterjee MeetaDirector–Jun 3, 20240
Eaton BruceEVP, CBO AND CTO74,791Dec 7, 20230
Robertson MichelleEVP, CHIEF FINANCIAL OFFICER106,610May 15, 20230
Shearman Mark SEVP, CHIEF SCIENTIFIC OFFICER65,559Feb 15, 20230
Mullen James CCEO75,898Apr 18, 20220
Michaels Lisa AnneEVP/Chief Medical Officer22,675Dec 23, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 4, 2026 (view filing)4:27 PM ETSep 31 dayBurkly LindaEVP, CHIEF SCIENTIFIC OFFICERSSale−709$3.04−$2.15K−1.1%61.7K after10b5-1
Sep 4, 2026 (view filing)4:25 PM ETSep 31 dayParison AmySVP, Chief Financial OfficerSSale−453$3.04−$1.38K−3.2%13.8K after10b5-1
Sep 4, 2026 (view filing)4:22 PM ETSep 31 dayO'Neill Gilmore NeilCEOSSale−5.12K$3.04−$15.6K−2.1%243.2K after10b5-1
Aug 5, 2026 (view filing)4:07 PM ETAug 32 daysParison AmySVP, Chief Financial OfficerSSale−678$2.58−$1.75K−4.5%14.3K after10b5-1
Jul 29, 2026 (view filing)4:51 PM ETJul 281 dayBurkly LindaEVP, CHIEF SCIENTIFIC OFFICERSSale−4.93K$2.67−$13.2K−7.3%62.4K after10b5-1
Jun 5, 2026 (view filing)Jun 32 daysParison AmySVP, Chief Financial OfficerSSale−464$2.70−$1.25K−3.0%15.0K after10b5-1
Jun 5, 2026 (view filing)Jun 32 daysO'Neill Gilmore NeilCEOSSale−15.4K$2.70−$41.5K−5.8%248.3K after10b5-1
Jun 5, 2026 (view filing)Jun 32 daysBurkly LindaEVP, CHIEF SCIENTIFIC OFFICERSSale−731$2.70−$1.97K−1.1%67.3K after10b5-1
Mar 4, 2026 (view filing)Mar 31 dayO'Neill Gilmore NeilCEOSSale−5.39K$2.02−$10.9K−2.0%263.7K after10b5-1
Mar 4, 2026 (view filing)Mar 31 dayParison AmySVP, Chief Financial OfficerSSale−474$2.02−$957.48−3.0%15.4K after10b5-1
Mar 4, 2026 (view filing)Mar 31 dayBurkly LindaEVP, CHIEF SCIENTIFIC OFFICERSSale−749$2.02−$1.51K−1.1%68.0K after10b5-1
Dec 4, 2025 (view filing)Dec 31 dayBurkly LindaEVP, CHIEF SCIENTIFIC OFFICERSSale−713$2.15−$1.53K−1.0%68.8K after10b5-1
Dec 4, 2025 (view filing)Dec 31 dayO'Neill Gilmore NeilCEOSSale−5.60K$2.15−$12.0K−2.0%269.1K after10b5-1
Dec 4, 2025 (view filing)Dec 31 dayParison AmySVP, Chief Financial OfficerSSale−461$2.15−$991.15−2.8%15.9K after10b5-1
Sep 4, 2025 (view filing)Sep 31 dayBurkly LindaEVP, CHIEF SCIENTIFIC OFFICERSSale−710$2.60−$1.85K−1.0%69.5K after10b5-1
Sep 4, 2025 (view filing)Sep 31 dayParison AmySVP, Chief Financial OfficerSSale−458$2.60−$1.19K−2.7%16.4K after10b5-1
Sep 4, 2025 (view filing)Sep 31 dayO'Neill Gilmore NeilCEOSSale−5.59K$2.60−$14.5K−2.0%274.7K after10b5-1
Aug 8, 2025 (view filing)Aug 71 dayParison AmySVP, Chief Financial OfficerSSale−679$2.58−$1.75K−3.9%16.8K after10b5-1
Aug 4, 2025 (view filing)Jul 314 daysBurkly LindaEVP, CHIEF SCIENTIFIC OFFICERSSale−5.12K$2.49−$12.8K−7.4%64.4K after10b5-1
Jun 4, 2025 (view filing)Jun 31 dayParison AmySVP, Chief Financial OfficerSSale−446$1.72−$767.12−2.5%17.5K after10b5-1
Jun 4, 2025 (view filing)Jun 31 dayBurkly LindaEVP, CHIEF SCIENTIFIC OFFICERSSale−726$1.72−$1.25K−1.0%69.5K after10b5-1
Jun 4, 2025 (view filing)Jun 31 dayO'Neill Gilmore NeilCEOSSale−15.2K$1.72−$26.1K−5.1%280.3K after10b5-1
Mar 5, 2025 (view filing)Mar 41 dayLucera ErickEVP, CHIEF FINANCIAL OFFICERSSale−4.11K$1.71−$7.03K−3.5%112.7K after10b5-1
Mar 5, 2025 (view filing)Mar 41 dayO'Neill Gilmore NeilCEOSSale−16.6K$1.71−$28.4K−5.3%295.5K after10b5-1
Mar 5, 2025 (view filing)Mar 41 dayBurkly LindaEVP, CHIEF SCIENTIFIC OFFICERSSale−2.89K$1.71−$4.94K−4.0%70.2K after10b5-1
Dec 5, 2024 (view filing)Dec 32 daysO'Neill Gilmore NeilCEOSSale−1.62K$2.08−$3.37K−0.5%312.1K after10b5-1
Dec 5, 2024 (view filing)Dec 32 daysMei BaisongEVP, CHIEF MEDICAL OFFICERSSale−541$2.08−$1.13K−0.4%133.4K after10b5-1
Sep 6, 2024 (view filing)Sep 42 daysMei BaisongEVP, CHIEF MEDICAL OFFICERSSale−518$3.42−$1.77K−0.4%133.9K after10b5-1
Sep 6, 2024 (view filing)Sep 42 daysO'Neill Gilmore NeilCEOSSale−1.55K$3.42−$5.32K−0.5%313.7K after10b5-1
Jul 26, 2024 (view filing)Jul 251 dayBurkly LindaEVP, CHIEF SCIENTIFIC OFFICERSSale−11.9K$5.42−$64.4K−14.0%73.1K after10b5-1
Jul 22, 2024 (view filing)Jul 193 daysMei BaisongEVP, CHIEF MEDICAL OFFICERSSale−6.62K$5.21−$34.5K−4.7%134.4K after10b5-1
Jun 6, 2024 (view filing)Jun 42 daysO'Neill Gilmore NeilCEOSSale−12.2K$5.50−$67.1K−3.7%315.3K after10b5-1
Jun 6, 2024 (view filing)Jun 42 daysMei BaisongEVP, CHIEF MEDICAL OFFICERSSale−511$5.50−$2.81K−0.4%141.0K after10b5-1
May 22, 2024 (view filing)May 202 daysLucera ErickEVP, CHIEF FINANCIAL OFFICERSSale−22.3K$5.61−$125.3K−16.1%116.8K after10b5-1
May 14, 2024 (view filing)May 131 dayHopfield JessicaDirectorPPurchase+45.0K$5.64+$253.8K+198.2%67.7K after
Mar 5, 2024 (view filing)Mar 5Same dayO'Neill Gilmore NeilCEOSSale−77.8K$9.42−$733.1K−19.2%327.5K after10b5-1
Mar 5, 2024 (view filing)Mar 41 dayMei BaisongSVP, CHIEF MEDICAL OFFICERSSale−20.3K$9.42−$191.5K−12.6%141.5K after10b5-1
Dec 7, 2023 (view filing)Dec 52 daysEaton BruceEVP, CBO AND CTOSSale−103$10.90−$1.12K−0.1%74.8K after10b5-1
Nov 16, 2023 (view filing)Nov 142 daysEaton BruceEVP, CBO AND CTOSSale−695$8.21−$5.71K−0.9%74.9K after10b5-1
Nov 9, 2023 (view filing)Nov 72 daysEaton BruceEVP, CBO AND CTOSSale−139$8.40−$1.17K−0.2%75.6K after10b5-1
Sep 7, 2023 (view filing)Sep 61 dayEaton BruceEVP, CBO AND CTOSSale−103$8.82−$908.46−0.1%75.7K after10b5-1
Aug 15, 2023 (view filing)Aug 114 daysEaton BruceEVP, CBO AND CTOSSale−702$8.59−$6.03K−0.9%75.8K after10b5-1
Aug 10, 2023 (view filing)Aug 82 daysEaton BruceEVP, CBO AND CTOSSale−141$8.39−$1.18K−0.2%76.5K after10b5-1
Jul 21, 2023 (view filing)Jul 192 daysMei BaisongSVP, CHIEF MEDICAL OFFICERSSale−4.32K$8.80−$38.0K−5.7%72.1K after10b5-1
Jun 7, 2023 (view filing)Jun 52 daysO'Neill Gilmore NeilCEOSSale−6.49K$9.50−$61.6K−4.7%130.2K after10b5-1
Jun 7, 2023 (view filing)Jun 52 daysEaton BruceEVP, CBO AND CTOSSale−105$9.50−$997.5−0.1%76.7K after10b5-1
May 15, 2023 (view filing)May 114 daysRobertson MichelleEVP, CHIEF FINANCIAL OFFICERSSale−949$9.87−$9.37K−0.9%106.6K after10b5-1
May 15, 2023 (view filing)May 114 daysEaton BruceEVP, CBO AND CTOSSale−668$9.87−$6.59K−0.9%76.8K after10b5-1
May 11, 2023 (view filing)May 92 daysEaton BruceEVP, CBO AND CTOSSale−135$9.51−$1.28K−0.2%77.4K after10b5-1
Mar 6, 2023 (view filing)Mar 33 daysRobertson MichelleEVP, CHIEF FINANCIAL OFFICERSSale−184$8.89−$1.64K−0.2%107.6K after